Intensive Blood Pressure Treatment for Resistant Hypertension.

Pubmed ID: 30580680

Pubmed Central ID: PMC6343947

Journal: Hypertension (Dallas, Tex. : 1979)

Publication Date: Feb. 1, 2019

MeSH Terms: Humans, Male, Female, Aged, Aged, 80 and over, Cardiovascular Diseases, Middle Aged, Hypertension, Randomized Controlled Trials as Topic, Proportional Hazards Models, Systole, Antihypertensive Agents

Authors: Tsujimoto T, Kajio H

Cite As: Tsujimoto T, Kajio H. Intensive Blood Pressure Treatment for Resistant Hypertension. Hypertension 2019 Feb;73(2):415-423.

Studies:

Abstract

Evidence about the target blood pressure (BP) in patients with resistant hypertension is limited. The present study aimed to assess the efficacy of intensive BP treatment (systolic BP target, <120 mm Hg) versus standard BP treatment (systolic BP target, <140 mm Hg) in patients with resistant hypertension. This is a secondary analysis using data from SPRINT (Systolic Blood Pressure Intervention Trial). This study included 1397 patients with resistant hypertension and 7698 without resistant hypertension. Using the Cox proportional hazards model, we compared time to first occurrence of a major adverse cardiovascular event (cardiovascular death, myocardial infarction, and stroke) between the intensive and standard BP treatment groups. Mean follow-up was 3.1 years; major adverse cardiovascular events was confirmed in 381 patients. Risk of major adverse cardiovascular events was significantly lower in the intensive treatment group than in the standard treatment group (hazard ratio, 0.62; 95% CI, 0.40-0.96; P=0.03). Risks of all-cause and cardiovascular death in patients with resistant hypertension were also significantly lower in the intensive treatment group than in the standard treatment group (hazard ratio for all-cause death: 0.60; 95% CI, 0.38-0.97; P=0.03; hazard ratio for cardiovascular death: 0.34; 95% CI, 0.15-0.81; P=0.01). Similar associations were observed in various subgroups. Intensive BP treatment was significantly associated with a decreased risk of major adverse cardiovascular events in patients with resistant hypertension.